MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceRadhika Mathur, J Costello, Yalan Zhang et al.|Neuro-Oncology|2020Cited by 96
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, David A. Solomon, Lucie McCoy et al.|Neuro-Oncology|2022Cited by 31